Atopic dermatitis (AD) is a heterogeneous disorder with varying phenotypes. Although AD has long been associated with barrier dysfunction, the pathogenesis of this disease is more complex, involving many molecular markers in different functional domains. Biomarkers can be helpful in different ways, including predicting prognosis, measuring treatment response, and gauging disease severity. With the advent of targeted immunomodulators, biomarkers have the potential to take on new significance in terms of selecting appropriate therapies for patients. In this review, we have summarized the key findings related to biomarkers and AD, including the specific subtype differences. Clinicians will use this information to better understand the potential of biomarkers in AD and have a guide because more specific treatments are developed that are tailored toward individual molecular profiles.
Get full access to this article
View all access options for this article.
References
1.
BrownSJ, McLeanWH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol, 2009; 129(3):543–552. doi:.
2.
EliasPM, SchmuthM. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol, 2009; 9(5):437–446. doi:.
3.
FurueM, TsujiG, MitomaC, et al.Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci, 2015; 80(2):83–88. doi:.
4.
HowellMD, KimBE, GaoP, et al.Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol, 2009; 124(3):R7–R12. doi:.
5.
SonkolyE, MullerA, LauermaAI, et al.IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol, 2006; 117(2):411–417. doi:.
6.
NodaS, Suárez-FariñasM, UngarB, et al.The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol, 2015; 136(5):1254–1264. doi:.
7.
HillDA, SpergelJM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol, 2018; 120:131–137 doi:10.1016/j.anai.2017.10.037.
8.
DarlenskiR, KazandjievaJ, HristakievaE, et al.Atopic dermatitis as a systemic disease. Clin Dermatol, 2014; 32:409–413. doi:10.1016/j.clindermatol.2013.11.007.
9.
ThyssenJP, ToftPB, Halling-OvergaardAS, et al.Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol, 2017; 77:280–286.e1. doi:10.1016/j.jaad.2017.03.003.
10.
SimonD, WardlawA, RothenbergME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol, 2010; 126:3–13. doi:10.1016/j.jaci.2010.01.055.
11.
SalsanoME, GrazianoL, LuongoI, et al.Atopy in childhood idiopathic nephrotic syndrome. Acta Paediatr, 2007; 96(4):561–566. doi:.
12.
O'ReganGM, IrvineAD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy, 2010; 40(7):965–972. doi:.
13.
BrunnerPM, IsraelA, ZhangN, et al.Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol, 2018; 141(6):2094–2106. doi:.
14.
KimBE, LeungDY, BoguniewiczM, et al.Loricrin and involucrin expression is down-regulated by TH2 cytokines through STAT-6. Clin Immunol, 2008; 126(3):332–337. doi:.
15.
OlssonM, BrobergA, JernåsM, et al.Increased expression of aquaporin 3 in atopic eczema. Allergy, 2006; 61(9):1132–1137. doi:.
16.
BhattAN, MathurR, FarooqueA, VermaA, DwarakanathBS. Cancer biomarkers - current perspectives. Indian J Med Res. 2010; 132:129–49.
17.
RalfkiaerU, LindahlLM, LitmanT, et al.MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res, 2014; 34:7207–7217.
18.
Suárez-FariñasM, DhingraN, GittlerJ, et al.Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol, 2013; 132(2):361–370. doi:.
19.
LandeckL, KneipC, ReischlJ, et al.Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Exp Dermatol, 2016; 25:333–339. doi:10.1111/exd.12948.
20.
NakaiK, YonedaK, MaedaR, et al.Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis. J Eur Acad Dermatol Venereol, 2009; 23:1405–1408. doi:10.1111/j.1468-3083.2009.03327.x.
21.
GutgesellC, HeiseS, SeubertA, et al.Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores. Br J Dermatol, 2002; 147:914–919. doi:10.1046/j.1365-2133.2002.04938.x.
22.
Guttman-YasskyE, DiazA, PavelAB, et al.Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol, 2019; 155:1358–1370. doi:10.1001/jamadermatol.2019.2983.
23.
Castelo-SoccioL.Stripping away barriers to find relevant skin biomarkers for pediatric atopic dermatitis. JAMA Dermatol, 2019. doi:10.1001/jamadermatol.2019.2792..
24.
KrathenRA, HsuS. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol, 2005; 53(2):338–340. doi:.
25.
KasperkiewiczM, SchmidtE, LudwigRJ, et al.Targeting IgE antibodies by immunoadsorption in atopic dermatitis. Front Immunol, 2018; 9:254. doi:10.3389/fimmu.2018.00254.
26.
DanbySG, ChittockJ, BrownK, et al.The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol, 2014; 170(4):914–921. doi:.
27.
SimpsonEL, VillarrealM, JepsonB, et al.Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol, 2018; 138:2224–2233. doi:10.1016/j.jid.2018.03.1517.
28.
ClausenM-L, AgnerT, LiljeB, et al.Association of disease severity with skin microbiome and filaggrin gene mutations in adult atopic dermatitis. JAMA Dermatol, 2018; 154(3):293–300. doi:.
29.
SeguchiT, CuiCY, KusudaS, et al.Decreased expression of filaggrin in atopic skin. Arch Dermatol Res, 1996; 288(8):442–446.
KezicS, O'ReganGM, YauN, et al.Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy, 2011; 66(7):934–940. doi:.
32.
HendersonJ, NorthstoneK, LeeSP, et al.The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol, 2008; 121(4):872–877.e9. doi:.
33.
O'ReganGM, KempermanPM, SandilandsA, et al.Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes. J Allergy Clin Immunol, 2010; 126(3):574–580.e1. doi:.
34.
BremmerSF, HanifinJM, SimpsonEL. Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: implications for allergic respiratory disease and prognosis. J Am Acad Dermatol, 2008; 59(1):72–78. doi:.
35.
GeogheganJA, IrvineAD, FosterTJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol, 2018; 26(6):484–497. doi:.
36.
MargolisDJ, GuptaJ, ApterAJ, et al.Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J Allergy Clin Immunol, 2014; 133:784–789. doi:10.1016/j.jaci.2013.09.015.
37.
LiangY, ChangC, LuQ. The genetics and epigenetics of atopic dermatitis—filaggrin and other polymorphisms. Clin Rev Allergy Immunol, 2016; 51:315–328. doi:10.1007/s12016-015-8508-5.
38.
ZhaoLP, DiZ, ZhangL, et al.Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. J Eur Acad Dermatol Venereol, 2012; 26:572–577. doi:10.1111/j.1468-3083.2011.04120.x.
39.
KatoA, FukaiK, OisoN, et al.Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol, 2003; 148:665–669. doi:10.1046/j.1365-2133.2003.05243.x.
40.
SanyalRD, PavelAB, GlickmanJ, et al.Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol, 2019; 122:99–110.e6. doi:10.1016/j.anai.2018.08.024.
41.
PugliarelloS, CozziA, GisondiP, et al.Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges, 2011; 9(1):12–20. doi:.
42.
JärvikallioA, HarvimaIT, NaukkarinenA. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res, 2003; 295(1):2–7. doi:.
43.
EsakiH, BrunnerPM, Renert-YuvalY, et al.Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol, 2016; 138(6):1639–1651. doi:.
44.
PaternosterL, SavenijeOEM, HeronJ, et al.Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol, 2018; 141(3):964–971. doi:.
45.
AmatF, Saint-PierreP, BourratE, et al.Early-onset atopic dermatitis in children: which are the phenotypes at risk of asthma? Results from the ORCA cohort. PLoS One, 2015; 10(6):e0131369. doi:10.1371/JOURNAL.PONE.0131369.
46.
KakinumaT, NakamuraK, WakugawaM, et al.Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol, 2002; 127(2):270–273. doi:.
47.
KagamiS, KakinumaT, SaekiH, et al.Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol, 2003; 134(2):309–313. doi:.
48.
HonKL, LeungTF, MaKC, et al.Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clin Exp Dermatol, 2004; 29(3):293–296. doi:.
49.
KataokaY.Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol, 2014; 41(3):221–229. doi:.
50.
MukaiH, NoguchiT, KamimuraK, et al.Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol, 1990; 17(8):477–481.
51.
WüthrichB, BenzA, SkvarilF. IgE and IgG4 levels in children with atopic dermatitis. Dermatologica, 1983; 166(5):229–235.
52.
LaskeN, NiggemannB.Does the severity of atopic dermatitis correlate with serum IgE levels?. Pediatr Allergy Immunol, 2004; 15(1):86–88.
53.
IyengarSR, HoyteEG, LozaA, et al.Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol, 2013; 162(1):89–93. doi:.
54.
JensenJM, SchererA, WankeC, et al.Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy, 2012; 67(3):413–423. doi:.
55.
BrunnerPM, KhattriS, GarcetS, et al.A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol, 2016; 138(1):169–178. doi:.
56.
HowellMD, NovakN, BieberT, et al.Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol, 2005; 125(4):738–745. doi:.
57.
TintleS, ShemerA, Suárez-FariñasM, et al.Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol, 2011; 128(3):583–93.e1–4. doi:.
58.
KhattriS, ShemerA, RozenblitM, et al.Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol, 2014; 133(6):1626–1634. doi:.
59.
LaraghJH, LamportB, SealeyJ, et al.Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension, 1988; 12(3):223–226.
60.
HamiltonJD, Suárez-FariñasM, DhingraN, et al.Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol, 2014; 134(6):1293–1300. doi:.
61.
SwansonB, MingJ, RenH, et al.Poster 1023: dupilumab suppresses TH2 inflammation in adult asthma and atopic dermatitis. World Allergy Organ J, 2014. doi:10.1186/1939-4551-7-s1-p13.
62.
AkinladeB, Guttman-YasskyE, de Bruin-WellerM, et al.Conjunctivitis in dupilumab clinical trials. Br J Dermatol, 2019:181:459–473. doi:10.1111/bjd.17869.
